- Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc’s (NASDAQ:NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.
- The analyst notes that though NBI-827104 lags behind its competitors, the market opportunity will be attractive given the total addressable market estimated at ~$13 billion, with no recently approved drugs in ET.
- The following data readout for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) and Praxis Precision Medicines Inc’s (NASDAQ:PRAX) second Phase 2 trials are expected in 1H of 2024 and 2H of 2022, respectively.
- Commenting on efficacy, given a similar mechanism of action to Jazz’s JZP385 and Praxis’ PRAX-944, Needham looks for a change in TETRAS-ADL of 5-6 points and TETRAS-ADL of 4-5 points.
- TETRAS is designed for the rapid and valid assessment of ET severity.
- On safety, JZP385 and PRAX-944 both had ~20% discontinuations.
- The analyst says that if NBI-827104’s safety profile can replicate its Phase 1 (~10% discontinuation).
- Needham expects a single-digit upside to shares on a successful study.
- Price Action: NBIX shares are up 1.77% at $97.26 during the market session on the last check Monday.
US Attorney Generals Seek Recall of Kia, Hyundai Vehicles in US
On Thursday, California Attorney General Rob Bonta and 17 other attorneys general urged the National Highway Traffic Safety…
